𝔖 Bobbio Scriptorium
✦   LIBER   ✦

HGF/MET-mediated resistance to dual HER2 and EGFR kinase inhibition in HER2 amplified gastric cancer cells

✍ Scribed by Chin-Tung Chen; David Liska; Martin R. Weiser

Book ID
113680157
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
95 KB
Volume
211
Category
Article
ISSN
1072-7515

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Anti-HER-3 MAbs inhibit HER-3-mediated s
Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies
✍ Edward Htun van der Horst; Marta Murgia; Martin Treder; Axel Ullrich πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 French βš– 386 KB

## Abstract Two members of the EGF receptor family, HER2 and HER3, act as key oncogenes in breast cancer cells. A MAb against HER2, trastuzumab, interferes with HER2 signaling and istherapeutically effective in humans. Here, we explored the biologic effects of an antibody against HER3 (α‐HER3^ECD^)

The dual EGFR/HER-2 tyrosine kinase inhi
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38
✍ Melissa J. LaBonte; Philipp C. Manegold; Peter M. Wilson; Will Fazzone; Stan G. πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 French βš– 482 KB

## Abstract Members of the human epidermal receptor (HER) family are frequently associated with aggressive disease and poor prognosis in multiple malignancies. Lapatinib is a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and HER‐2. This study evaluated the the